U.S. Markets close in 6 hrs 2 mins

Preclinical biotech Stoke Therapeutics plans $86M IPO

Allison DeAngelis
Preclinical biotech Stoke Therapeutics plans $86M IPO

An RNA-altering startup led by some of the brains behind Biogen and Sarepta Therapeutics' blockbuster products is hoping to raise $86 million in an IPO, it disclosed Thursday.